Relapsed Mantle Cell Lymphoma Presenting as “Sister Mary Joseph Nodule” by Vaughn, Jennifer E. & Gopal, Ajay K.
Hindawi Publishing Corporation
Case Reports in Medicine




“Sister Mary Joseph Nodule”
Jennifer E. Vaughn1 andAjayK.Gopal1,2,3
1Department of Internal Medicine, University of Washington, Box 39892. 325 Ninth Ave., Seattle,
WA 98104, USA
2Clinical Research Division, Fred Hutchinson Research Center, Seattle, WA, USA
3Seattle Cancer Care Alliance, Mailstop G6-800, 825 Eastlake Ave. E Seattle, WA 98109, USA
Correspondence should be addressed to Jennifer E. Vaughn, jev5@u.washington.edu
Received 6 January 2010; Accepted 25 February 2010
Academic Editor: Werner Rabitsch
Copyright © 2010 J. E. Vaughn and A. K. Gopal. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
The ﬁnding of umbilical metastasis has historically been called a “Sister Mary Joseph Nodule”. A few case reports of lymphoma
presenting in this manner have been documented. We report a case of relapsed mantle cell lymphoma (MCL) presenting as a Sister
Mary Joseph’s nodule. Although the few reports of lymphoma exhibiting umbilical metastasis suggest that patients may still expect
areasonableresponsetochemotherapy,thispatientexperiencedmultiplerelapses,despiteaggressivechemotherapyregimens.This
clinical course is characteristic of the mantle cell form of non-hodgkin’s lymphoma and illustrates a need to seek out more eﬀective
therapies.
1.Introduction
Umbilical malignant metastasis is a rare sign of advanced
malignancy and usually associated with cancers of the
gastrointestinal and reproductive tract [1]. The term “Sister
Mary Joseph’s nodule” was coined by Sir Hamilton Bailey,
after Sister Mary Joseph Dempsey (1856–1939) who served
as surgical assistant to Dr. William Mayo in Rochester, MN.
She was the ﬁrst to observe the association between umbil-
ical nodules, which she named “pants button umbilicus,”
and metastatic intraabdominal disease. This discovery was
published in 1928 [2]. As was also noted by its namesake,
it is generally thought to signify a poor prognosis, with mean
survival reported between 8 and 11 months [1, 3, 4].
Interestingly, reports of hematological malignancies pre-
sentinginthismannerareexceedinglyuncommonandwhen
reported, do not necessarily represent intractable disease. In
a review of 407 cases of SMJ nodules, only 1 was noted to
be of lymphomatous origin [5, 6]. Further review of the
literaturerevealedﬁvecasesofSJMnodulesdeterminedtobe
from metastatic lymphoma [5–10] with four demonstrating
signiﬁcant responses to chemotherapy [7–10]a n dt w o[ 7, 8]
achieving complete remission. All ﬁve case reports identiﬁed
the malignancy as non-Hodgkin lymphoma and two of these
were speciﬁcally identiﬁed as large B-cell lymphomas [8, 9].
NonewereofMCLorigin.Infact,adedicatedsearchrevealed
no cases of MCL presenting as SMJ nodule in the literature.
2.CaseReport
A 72-year-old male with a history of previously treated
blastic variant (Ki-67 60%–70%) mantle cell lymphoma
(MCL) presented to his outpatient oncology clinic with
new complaints consisting of diﬀuse abdominal pain and
distention, night sweats, fatigue, and a new mass within
the umbilicus. The patient was noted to have a Mantle Cell
Lymphoma International Prognostic Index (MIPI) [11]o f6 ,
primarily receiving a high risk score due to age >70 and an
LDH which was 1.4 times the upper limit of normal. The
patient’s performance status was limited only by weakness
attributed to chronic narcotic use, but he was otherwise very
functional at the time of presentation.
Recurrence was noted by PET scan to have occurred in








the diaphragm, the retroperitoneum, and the right pelvis.
However,abdominalexaminationrevealedanew,nontender,
violaceous mass projecting from the umbilicus (Figure 1).
Computerized tomography of the chest, abdomen and pelvis
conﬁrmed the presence of the lesion within the umbilical
cavity and also demonstrated an abdominal mass measuring
20.7cm×30cm×13cm abutting the stomach against the
diaphragm (Figure 2). This constellation of ﬁndings was
thought to represent relapsed MCL and the protuberant
abdominal mass consistent with the ﬁnding of a Sister Mary
Joseph’s (SMJ) nodule. The patient experienced multiple
relapses after R-CHOP, single agent rituximab, bortezomib,
and gemcitabine-carboplatin-dexamethsone-rituximab. Fol-
lowing this most recent relapse, he experienced a transient
response to cyclophosphamide, etoposide, dexamethasone,
and rituximab, but unfortunately expired 11 months later
after further tumor progression.
3. Discussion
MCL is characterized by frequent extranodal involvement
with a predilection to the aerodigestive tract, though
ocular, central nervous system, breast, skin, and testicular
involvement have been reported [12–17]. Studies meant to
characterize the frequency of spread to these sites are often
limited by low case numbers and methodology of patient
selection. Clinically signiﬁcant gastrointestinal involvement
has been historically reported in 15%–30% of cases [18–21]
although studies of random biopsy specimens from the GI
tracts of untreated MCL patients suggest that this number
may much higher [18, 22]. Central nervous system (CNS)
inﬁltration has been described in anywhere of 2%–23%
of MCL patients[15, 23, 24] and was associated with high
tumor proliferative rate, blastic variant, and elevated lactate
dehydrogenase [25]. Factors associated with other sites of
extranodal disease beyond the gastrointestinal tract, bone
marrow, and CNS are less well described but are also likely
correlated with these same factors.
In general, MCL is characterized by lack of sustained
responses to conventional therapies and poorer outcomes
when compared to other lymphomas. While ﬁve-year sur-
vival after standard R-CHOP therapy was recently demon-
strated to have improved from 22% to 47% [26], worse
outcomes are associated with the presence of >1 entranodal
site of disease [20, 27]. This case presentation illustrates both
another unusual extranodal manifestation of MCL and the
still grave prognosis of this entity emphasizing the need for
more eﬀective treatments.
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